KR20250117744A - Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체 - Google Patents

Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체

Info

Publication number
KR20250117744A
KR20250117744A KR1020257025325A KR20257025325A KR20250117744A KR 20250117744 A KR20250117744 A KR 20250117744A KR 1020257025325 A KR1020257025325 A KR 1020257025325A KR 20257025325 A KR20257025325 A KR 20257025325A KR 20250117744 A KR20250117744 A KR 20250117744A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257025325A
Other languages
English (en)
Korean (ko)
Inventor
에릭 트란
용-천 루
스티븐 에이 로젠버그
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20250117744A publication Critical patent/KR20250117744A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
KR1020257025325A 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체 Pending KR20250117744A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras
KR1020187010326A KR102841067B1 (ko) 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010326A Division KR102841067B1 (ko) 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체

Publications (1)

Publication Number Publication Date
KR20250117744A true KR20250117744A (ko) 2025-08-05

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257025325A Pending KR20250117744A (ko) 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체
KR1020187010326A Active KR102841067B1 (ko) 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187010326A Active KR102841067B1 (ko) 2015-09-15 2016-09-09 Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체

Country Status (13)

Country Link
US (3) US10556940B2 (https=)
EP (2) EP3901169B1 (https=)
JP (2) JP7185524B2 (https=)
KR (2) KR20250117744A (https=)
CN (2) CN115073583A (https=)
AU (3) AU2016323017B2 (https=)
DK (1) DK3350213T3 (https=)
ES (1) ES2879287T3 (https=)
IL (1) IL257840B2 (https=)
MX (1) MX2018003062A (https=)
SA (1) SA518391109B1 (https=)
SG (1) SG10201913868XA (https=)
WO (1) WO2017048593A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
HRP20221183T1 (hr) * 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110612446B (zh) * 2017-03-31 2023-07-04 美国卫生和人力服务部 分离新抗原-特异性t细胞受体序列的方法
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
CR20200287A (es) 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
JP2021533777A (ja) 2018-08-16 2021-12-09 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
EP3914612A1 (en) * 2019-01-22 2021-12-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
US20210342750A1 (en) * 2019-08-14 2021-11-04 Nec Corporation Information processing apparatus, information processing method, and storage medium
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
KR20220143875A (ko) * 2020-02-14 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
AU2021309958A1 (en) * 2020-07-16 2023-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted DRB T cell receptors against RAS with G12V mutation
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CN118994363A (zh) 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体

Also Published As

Publication number Publication date
IL257840B1 (en) 2023-06-01
AU2016323017B2 (en) 2020-11-12
KR20180044428A (ko) 2018-05-02
US20230406904A1 (en) 2023-12-21
IL257840A (en) 2018-04-30
US20190040111A1 (en) 2019-02-07
JP2023025108A (ja) 2023-02-21
JP2018535647A (ja) 2018-12-06
US10556940B2 (en) 2020-02-11
JP7185524B2 (ja) 2022-12-07
AU2022209229A1 (en) 2022-09-15
AU2021200833B2 (en) 2022-04-28
SG10201913868XA (en) 2020-03-30
CN108350059A (zh) 2018-07-31
EP3350213A1 (en) 2018-07-25
SA518391109B1 (ar) 2022-02-14
EP3901169B1 (en) 2026-01-28
CN115073583A (zh) 2022-09-20
EP3350213B1 (en) 2021-03-31
DK3350213T3 (da) 2021-06-21
US20200148739A1 (en) 2020-05-14
CN108350059B (zh) 2021-10-08
ES2879287T3 (es) 2021-11-22
US11667692B2 (en) 2023-06-06
IL257840B2 (en) 2023-10-01
AU2022209229B2 (en) 2024-05-23
MX2018003062A (es) 2018-09-11
HK1257902A1 (en) 2019-11-01
JP7461445B2 (ja) 2024-04-03
AU2016323017A1 (en) 2018-04-05
KR102841067B1 (ko) 2025-08-01
EP3901169A1 (en) 2021-10-27
WO2017048593A1 (en) 2017-03-23
AU2021200833A1 (en) 2021-03-04
CA2998869A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
KR102527052B1 (ko) 항-kras-g12d t 세포 수용체
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
KR20200115484A (ko) 돌연변이 ras에 대한 hla 클래스 i-제한 t 세포 수용체
KR20220143867A (ko) G12d 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
WO2022177961A1 (en) Hla class i–restricted t cell receptors against cd22
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
EP4612169A1 (en) Hla-a3-restricted t cell receptors against braf with v600e mutation

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)